International Journal of Surgical Oncology

metrics 2024

Transforming surgical oncology through open access knowledge.

Introduction

The International Journal of Surgical Oncology, published by HINDAWI LTD, stands as a pivotal resource within the realms of surgical and oncology research, with a commendable impact on the field since its inception. Established as an Open Access journal in 2010, it facilitates the dissemination of high-quality, peer-reviewed research that is accessible to a global audience, ensuring that the latest advancements in surgical techniques and oncology treatments reach researchers, practitioners, and students alike. With its current standings of Q3 in Oncology and Q2 in Surgery, alongside impressive Scopus rankings—150/551 in Medicine _ Surgery and 224/404 in Medicine _ Oncology—the journal is recognized for its influential contributions to these critical medical fields. Covering a wide array of topics from innovative surgical methods to comprehensive cancer care approaches, the journal aims to foster collaboration and knowledge-sharing among professionals seeking to enhance patient outcomes across diverse surgical oncology practices. With continued convergence of research from 2012 to 2024, the journal remains at the forefront of addressing contemporary challenges faced in surgical oncology today.

Metrics 2024

SCIMAGO Journal Rank0.42
Journal Impact Factor1.60
Journal Impact Factor (5 years)2.30
H-Index30
Journal IF Without Self1.60
Eigen Factor0.00
Normal Eigen Factor0.05
Influence0.58
Immediacy Index0.10
Cited Half Life10.80
Citing Half Life-
JCI0.37
Total Documents184
WOS Total Citations416
SCIMAGO Total Citations1034
SCIMAGO SELF Citations5
Scopus Journal Rank0.42
Cites / Document (2 Years)1.72
Cites / Document (3 Years)1.71
Cites / Document (4 Years)1.70

Metrics History

Rank 2024

Scopus

Surgery in Medicine
Rank #150/551
Percentile 72.78
Quartile Q2
Oncology in Medicine
Rank #224/404
Percentile 44.55
Quartile Q3

IF (Web Of Science)

ONCOLOGY
Rank 253/322
Percentile 21.60
Quartile Q4

JCI (Web Of Science)

ONCOLOGY
Rank 251/322
Percentile 22.05
Quartile Q4

Quartile History

Similar Journals

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Advancing knowledge in colorectal health.
Publisher: SPRINGERISSN: 0179-1958Frequency: 1 issue/year

International Journal of Colorectal Disease is a prestigious peer-reviewed journal published by Springer that focuses on the evolving landscape of colorectal diseases. Established in 1986, this journal has served as a vital platform for researchers, healthcare professionals, and students to explore groundbreaking research, innovative treatment methodologies, and the latest advancements in gastroenterology. With an impressive impact factor and ranked in the Q2 category of gastroenterology by Scopus, it holds a prominent position in the academic community, currently occupying the 59th rank among 167 journals in the field, corresponding to the 64th percentile. Although it does not offer open access, the journal remains invaluable for those seeking in-depth analysis and comprehensive insights into colorectal health issues. As it continues through its convergence years until 2024, the International Journal of Colorectal Disease invites contributions that aim to bridge the gap between research and clinical practice, fostering a deeper understanding of colorectal disorders and enhancing patient care.

Actas Urologicas Espanolas

Exploring Breakthroughs in Urological Medicine
Publisher: ELSEVIER ESPANAISSN: 0210-4806Frequency: 10 issues/year

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

Current Oncology

Pioneering Open Access in Cancer Studies
Publisher: MDPIISSN: 1198-0052Frequency: 12 issues/year

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

Translational Lung Cancer Research

Empowering global collaboration in lung cancer research.
Publisher: AME PUBLISHING COMPANYISSN: 2218-6751Frequency: 6 issues/year

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

European Urology Oncology

Driving interdisciplinary collaboration for better patient outcomes.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Breast Care

Advancing Breast Health Through Research and Innovation
Publisher: KARGERISSN: 1661-3791Frequency: 6 issues/year

Breast Care is a prominent academic journal published by KARGER, focusing on the dynamic fields of oncology and surgery. With an ISSN of 1661-3791 and an E-ISSN of 1661-3805, this peer-reviewed journal has established itself as an essential resource for researchers, clinicians, and students dedicated to advancing breast health. Based in Switzerland, it benefits from a strong academic reputation, evident in its impressive Scopus rankings—placing it in the 79th percentile in Surgery (Rank #115/551) and the 53rd percentile in Oncology (Rank #188/404). The journal is recognized for its rigorous exploration of current trends, innovations, and challenges in breast care, encompassing a wide scope from surgical techniques to oncological therapies. With a Q2 ranking in Oncology and a notable Q1 ranking in Surgery as of 2023, Breast Care not only contributes to the advancement of medical knowledge but also fosters interdisciplinary collaboration among healthcare professionals worldwide.

Oncology Letters

Pioneering Research for a Brighter Future in Oncology
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

EJSO

Elevating surgical practices with impactful research.
Publisher: ELSEVIER SCI LTDISSN: 0748-7983Frequency: 12 issues/year

The European Journal of Surgical Oncology (EJSO), published by Elsevier Science Ltd, stands as a leading international journal dedicated to the field of surgical oncology. With an ISSN of 0748-7983 and an E-ISSN of 1532-2157, EJSO has been a key resource for researchers and practitioners since its inception in 1985, covering a wide spectrum of topics in advanced surgical techniques, oncology practices, and multidisciplinary approaches to cancer treatment. The journal boasts impressive rankings, being classified in the Q1 quartile for Medicine (Miscellaneous) and Surgery, and Q2 in Oncology for 2023, reflecting its high impact within the scientific community, with a Scopus ranking of #36/551 in Medicine and Surgery, placing it in the 93rd percentile. Although it does not currently offer Open Access options, EJSO remains committed to advancing the field through reliable research and innovative surgical methodologies. Its ongoing contributions are invaluable for those engaged in the continuous improvement of cancer treatment and management.

World Journal of Surgical Oncology

Bridging research and practice in the world of surgical oncology.
Publisher: BMCISSN: Frequency: 1 issue/year

The World Journal of Surgical Oncology, published by BMC, is a leading open-access journal that has been disseminating high-quality research since 2003. With an impressive impact, it currently holds a Q2 ranking in Oncology and a Q1 ranking in Surgery for the year 2023, reflecting its significant contribution to the field. Based in the United Kingdom, this journal serves as a vital platform for researchers, clinicians, and students alike, offering comprehensive coverage on topics ranging from innovative surgical techniques to oncology treatment advancements. As part of the esteemed BMC portfolio, the journal leverages a robust editorial process to ensure the publication of impactful research articles that promote a deeper understanding and enhancement of surgical oncology practices. Its commitment to open access ensures that critical research findings are widely accessible, fostering collaboration and knowledge sharing within the global medical community. For those dedicated to advancing their expertise in surgical oncology, the World Journal of Surgical Oncology is an indispensable resource that reflects the forefront of research and clinical practice.

Bladder Cancer

Transforming knowledge into patient care in urology.
Publisher: IOS PRESSISSN: 2352-3727Frequency: 4 issues/year

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.